CL2013002579A1 - Preparacion solida que comprende 6-((7s)-7-hidroxi-6,7-dihidro-5h-pirrolo[1,2-c]imidazol-7-il)-n-metil-2-naftamida, d-manitol y una sal de metal alcalinoterreo seleccionada de aluminometasilicato de magnesio y silicato de calcio; y metodo de estabilizacion del compuesto, util para la prevencion o el tratamiento de tumores. - Google Patents

Preparacion solida que comprende 6-((7s)-7-hidroxi-6,7-dihidro-5h-pirrolo[1,2-c]imidazol-7-il)-n-metil-2-naftamida, d-manitol y una sal de metal alcalinoterreo seleccionada de aluminometasilicato de magnesio y silicato de calcio; y metodo de estabilizacion del compuesto, util para la prevencion o el tratamiento de tumores.

Info

Publication number
CL2013002579A1
CL2013002579A1 CL2013002579A CL2013002579A CL2013002579A1 CL 2013002579 A1 CL2013002579 A1 CL 2013002579A1 CL 2013002579 A CL2013002579 A CL 2013002579A CL 2013002579 A CL2013002579 A CL 2013002579A CL 2013002579 A1 CL2013002579 A1 CL 2013002579A1
Authority
CL
Chile
Prior art keywords
naphthamide
pyrrolo
imidazol
dihydro
tumors
Prior art date
Application number
CL2013002579A
Other languages
English (en)
Inventor
Masafumi Misaki
Wataru Hoshina
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46018066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013002579(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2013002579A1 publication Critical patent/CL2013002579A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
CL2013002579A 2011-04-01 2013-09-09 Preparacion solida que comprende 6-((7s)-7-hidroxi-6,7-dihidro-5h-pirrolo[1,2-c]imidazol-7-il)-n-metil-2-naftamida, d-manitol y una sal de metal alcalinoterreo seleccionada de aluminometasilicato de magnesio y silicato de calcio; y metodo de estabilizacion del compuesto, util para la prevencion o el tratamiento de tumores. CL2013002579A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011082301 2011-04-01

Publications (1)

Publication Number Publication Date
CL2013002579A1 true CL2013002579A1 (es) 2014-01-24

Family

ID=46018066

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002579A CL2013002579A1 (es) 2011-04-01 2013-09-09 Preparacion solida que comprende 6-((7s)-7-hidroxi-6,7-dihidro-5h-pirrolo[1,2-c]imidazol-7-il)-n-metil-2-naftamida, d-manitol y una sal de metal alcalinoterreo seleccionada de aluminometasilicato de magnesio y silicato de calcio; y metodo de estabilizacion del compuesto, util para la prevencion o el tratamiento de tumores.

Country Status (28)

Country Link
US (3) US20150157609A1 (es)
EP (1) EP2694039B1 (es)
JP (1) JP6077459B2 (es)
KR (1) KR20140018923A (es)
CN (1) CN103458878B (es)
AR (1) AR085743A1 (es)
AU (1) AU2012233203A1 (es)
BR (1) BR112013022010A2 (es)
CA (1) CA2831548A1 (es)
CL (1) CL2013002579A1 (es)
CO (1) CO6821945A2 (es)
CR (1) CR20130481A (es)
DO (1) DOP2013000217A (es)
EA (1) EA201391447A1 (es)
EC (1) ECSP13012905A (es)
ES (1) ES2607070T3 (es)
GE (1) GEP20156306B (es)
IL (1) IL228357A0 (es)
MA (1) MA35069B1 (es)
MX (1) MX2013010661A (es)
PE (1) PE20141009A1 (es)
PH (1) PH12013502038A1 (es)
SG (1) SG193328A1 (es)
TN (1) TN2013000356A1 (es)
TW (1) TW201244757A (es)
UY (1) UY33996A (es)
WO (1) WO2012133918A1 (es)
ZA (1) ZA201306799B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112206218B (zh) * 2020-10-24 2022-08-23 迪沙药业集团有限公司 一种甲硝唑维生素b6组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3145146A (en) * 1961-10-31 1964-08-18 Warner Lambert Pharmaceutical Modified mannitol for pharmaceutical tablets
DE60119963T2 (de) 2000-11-17 2006-10-05 Takeda Pharmaceutical Co. Ltd. Imidazol derivate, ihre herstellung und ihre verwendung
JP2002308760A (ja) * 2001-04-06 2002-10-23 Taiyo Yakuhin Kogyo Kk 圧縮成型用組成物及びその利用
WO2004075890A1 (ja) 2003-02-26 2004-09-10 Takeda Pharmaceutical Company 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾ－ル誘導体の安定化方法
JP4745616B2 (ja) * 2003-02-26 2011-08-10 武田薬品工業株式会社 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法
CA2519211A1 (en) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Release control compositions
CA2610343A1 (en) 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited Release-control composition
JP2011082301A (ja) 2009-10-06 2011-04-21 Sony Corp 配線基板、その製造方法および電子機器

Also Published As

Publication number Publication date
DOP2013000217A (es) 2013-12-31
EA201391447A1 (ru) 2014-02-28
MX2013010661A (es) 2013-10-28
EP2694039B1 (en) 2016-09-21
SG193328A1 (en) 2013-10-30
CA2831548A1 (en) 2012-10-04
ZA201306799B (en) 2014-11-26
CN103458878B (zh) 2015-11-25
US20150157609A1 (en) 2015-06-11
AU2012233203A1 (en) 2013-10-10
GEP20156306B (en) 2015-06-25
AR085743A1 (es) 2013-10-23
ECSP13012905A (es) 2013-11-29
JP2014509586A (ja) 2014-04-21
BR112013022010A2 (pt) 2016-11-29
TN2013000356A1 (en) 2015-01-20
TW201244757A (en) 2012-11-16
CN103458878A (zh) 2013-12-18
US20170202777A1 (en) 2017-07-20
KR20140018923A (ko) 2014-02-13
CO6821945A2 (es) 2013-12-31
CR20130481A (es) 2013-10-23
US20190054026A1 (en) 2019-02-21
EP2694039A1 (en) 2014-02-12
MA35069B1 (fr) 2014-04-03
PH12013502038A1 (en) 2013-12-16
IL228357A0 (en) 2013-12-31
ES2607070T3 (es) 2017-03-29
UY33996A (es) 2012-10-31
NZ615452A (en) 2015-05-29
PE20141009A1 (es) 2014-09-04
JP6077459B2 (ja) 2017-02-08
WO2012133918A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
PH12016501535A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
EA201491456A1 (ru) Соединения-ингибиторы raf
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
IL240030A0 (en) 2-aza-bicyclo[1.2.2]heptane-3-carboxylic acid (benzyl-cyano-methyl)-modified amides inhibitors of cathepsin c
EA201591509A1 (ru) Ингибиторы cdc7
MX355632B (es) Inhibidores de la trayectoria de señalización notch y uso de los mismos en el tratamiento de cánceres.
MX347257B (es) Solido de gamma-carbolinas fusionadas con heterociclos substituidos.
PL2721118T3 (pl) Sposób hamowania lub kontrolowania uwalniania środka do obróbki odwiertu
EA201490161A1 (ru) Соединения - ингибиторы сигналинга, опосредуемого рецептором notch
CR20120448A (es) Compuesto heterocíclico
CU20110159A7 (es) Pirimidinas fusionadas
MX360774B (es) Antagonistas de progesterona.
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
CL2011001947A1 (es) Compuestos derivados de fenil-{1,2,4}triazolo[1,5-a]piridin-fenilamino sustituidos, inhibidores de cinasa; utiles para tratar trastornos asociados con la permeabilidad vascular.
EP2693882A4 (en) SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS WITH SUCH COMPOUNDS AND TREATMENT METHODS THEREWITH
MX2013013891A (es) Sistema y metodo de tratamiento de agua anti-incrustaciones.
EP2720544A4 (en) SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS WITH SUCH COMPOUNDS AND TREATMENT METHODS THEREWITH
EA201400214A1 (ru) Антраниламидные соединения и их применение в качестве пестицидов
EA201170447A1 (ru) Производные изохинолинона в качестве антагонистов nk3
EP2569001A4 (en) PROCEDURE FOR TREATING OR PREVENTING KIDNEY OR REFUSE FUNCTIONS
EP2760855A4 (en) SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING THESE COMPOUNDS, AND METHODS OF TREATMENT
CL2013002579A1 (es) Preparacion solida que comprende 6-((7s)-7-hidroxi-6,7-dihidro-5h-pirrolo[1,2-c]imidazol-7-il)-n-metil-2-naftamida, d-manitol y una sal de metal alcalinoterreo seleccionada de aluminometasilicato de magnesio y silicato de calcio; y metodo de estabilizacion del compuesto, util para la prevencion o el tratamiento de tumores.
EA201591480A1 (ru) Способы лечения дискинезии и сопутствующих расстройств
PH12016500809A1 (en) Glucopyranosyl - substituted indole-urea derivatives and their use as sglt inhibitors